The ADAPTED (Alzheimer’s Disease Apolipoprotein Pathology for Treatment Elucidation and Development) project is a major new initiative to investigate an area of Alzheimer’s Disease (AD) research which has previously received little attention. The project aims to improve understanding of the function of the APOE gene. APOE is well known as a risk factor for developing the disease but precisely how this gene contributes to the risk of developing AD is not known.
ADAPTED brings together the expertise of researchers in universities, research institutes and biotech and pharmaceutical companies from across Europe and the USA. Using the expertise of the ADAPTED partners in a range of cutting-edge biological analysis methods the project will attempt to really unravel the complexities of the APOE gene as well as providing the research community with a new generation of human cell –based tools to mimic and investigate the causes and progression of the disease.
The impact of this work can be expected to include seminal new finding to illuminate the research path towards new diagnostics and therapies to attenuate the rising tide of suffering from AD. The vision is a follow on with clinical proof of concept validating utility of the results within two years of the end of ADAPTED.